SVB Leerink upgraded shares of Enhabit (NYSE:EHAB - Free Report) from an underperform rating to a market perform rating in a research report released on Tuesday, MarketBeat.com reports. SVB Leerink currently has $8.50 price target on the stock.
EHAB has been the subject of several other reports. UBS Group raised Enhabit from a sell rating to a neutral rating and set a $9.50 price target for the company in a report on Thursday, March 7th. Jefferies Financial Group cut shares of Enhabit from a buy rating to a hold rating and reduced their target price for the company from $14.00 to $8.75 in a research report on Thursday, May 9th. Finally, Oppenheimer reaffirmed a market perform rating on shares of Enhabit in a research report on Thursday, March 7th. One analyst has rated the stock with a sell rating and six have issued a hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of Hold and an average price target of $10.13.
Check Out Our Latest Analysis on Enhabit
Enhabit Trading Up 4.5 %
Shares of EHAB stock traded up $0.39 on Tuesday, reaching $9.03. 1,161,836 shares of the stock were exchanged, compared to its average volume of 595,470. The stock has a 50 day moving average price of $10.39 and a 200 day moving average price of $10.07. Enhabit has a one year low of $7.12 and a one year high of $14.59. The stock has a market cap of $452.85 million, a PE ratio of -5.44, a P/E/G ratio of 1.36 and a beta of 1.98. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.50 and a quick ratio of 1.50.
Enhabit (NYSE:EHAB - Get Free Report) last issued its quarterly earnings results on Wednesday, March 6th. The company reported $0.03 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.01. The company had revenue of $260.60 million for the quarter, compared to analyst estimates of $260.30 million. Enhabit had a positive return on equity of 1.43% and a negative net margin of 7.95%. During the same period in the previous year, the company posted $0.32 earnings per share. Equities research analysts forecast that Enhabit will post 0.24 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, Director Jeffrey Bolton purchased 10,000 shares of the business's stock in a transaction that occurred on Friday, May 10th. The shares were bought at an average price of $8.24 per share, for a total transaction of $82,400.00. Following the purchase, the director now directly owns 42,299 shares of the company's stock, valued at approximately $348,543.76. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.90% of the company's stock.
Hedge Funds Weigh In On Enhabit
Institutional investors and hedge funds have recently modified their holdings of the company. SummerHaven Investment Management LLC raised its position in shares of Enhabit by 1.8% during the 4th quarter. SummerHaven Investment Management LLC now owns 58,947 shares of the company's stock valued at $610,000 after purchasing an additional 1,038 shares during the period. Brooks Moore & Associates Inc. raised its position in shares of Enhabit by 5.1% during the third quarter. Brooks Moore & Associates Inc. now owns 26,950 shares of the company's stock valued at $303,000 after buying an additional 1,300 shares during the last quarter. Oppenheimer & Co. Inc. boosted its stake in Enhabit by 7.2% during the first quarter. Oppenheimer & Co. Inc. now owns 26,224 shares of the company's stock valued at $306,000 after buying an additional 1,768 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Enhabit by 13.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 16,058 shares of the company's stock valued at $166,000 after acquiring an additional 1,875 shares during the last quarter. Finally, Illinois Municipal Retirement Fund grew its holdings in shares of Enhabit by 10.7% in the first quarter. Illinois Municipal Retirement Fund now owns 33,042 shares of the company's stock valued at $385,000 after purchasing an additional 3,193 shares in the last quarter.
Enhabit Company Profile
(
Get Free Report)
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
Featured Articles
Before you consider Enhabit, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enhabit wasn't on the list.
While Enhabit currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
